Select the drug indication to add to your list


Only 4 drugs may be compared at once

Generic Name and Formulations:

Drospirenone 3mg, ethinyl estradiol 30micrograms, levomefolate calcium 0.451mg (21 tablets); levomefolate calcium 0.451mg (7 tablets).

Select therapeutic use:

Indications for SAFYRAL:

Oral contraception. To raise folate ­levels in women who choose to use an OC for contraception.


1 tablet daily for 28 days; repeat. Take at the same time daily. Use Day 1 or Sunday start for 1st cycle; use backup method for first 7 days.


Pre-menarche: not applicable.


Renal impairment. Adrenal insufficiency. High risk of arterial or venous thrombotic disease (eg, smokers or migraineurs over age 35, history of DVT or thromboembolism, cerebrovascular or coronary artery disease, thrombogenic valvular disease, atrial fibrillation, subacute bacterial endocarditis, hypercoagulopathies, uncontrolled hypertension, diabetes with vascular disease, headaches with focal neurologic symptoms). Breast or other estrogen or progestin-sensitive neoplasms. Hepatic disease or tumors. Undiagnosed abnormal uterine bleeding. Pregnancy.


Discontinue if thrombotic event, unexplained visual changes, jaundice, or severe migraine occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism. Hyperkalemia or risk thereof. Diabetes. Prediabetes. Uncontrolled dyslipidemias. Pregnancy-related cholestasis. History of depression; monitor and discontinue if serious depression recurs. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea. Do regular complete physical exams. Monitor BP; discontinue if significant rise occurs. Nursing mothers: not recommended.


Monitor serum K+ during 1st cycle with drugs that increase potassium (eg, ACE inhibitors, ARBs, NSAIDs, K+-sparing diuretics, K+ supplements, heparin, aldosterone antagonists); consider monitoring in high-risk patients taking concomitant long-term strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, indinavir, boceprevir, clarithromycin). May be antagonized by CYP3A4 or other enzyme inducers (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's wort, topiramate) (use backup contraception). May be affected by pro­tease inhibitors, NNRTIs, acetaminophen, ascorbic acid, itraconazole, ketoconazole. May antagonize lamotrigine. May affect laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). May need dose adjustment of thyroid hormones. May mask vitamin B12 deficiency (folate).

Pharmacological Class:

Progestin + estrogen + folate.

Adverse Reactions:

Premenstrual syndrome, headache/migraine, breast pain/tenderness, hypertension, nausea, vomiting, mood changes, abdominal pain/tenderness/discomfort, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, intolerance to contact lenses; increased risk of gallbladder disease, thromboembolic disorders.

How Supplied:

Packs—3 (3x28 day cycles)

SAFYRAL 28 tablets packages (Qty:1)

appx. price $195.00